Medscape

Update on the Pharmacogenomics of Proton Pump Inhibitors

Genetic polymorphisms have been described in the case of several CYP isoenzymes. The best explored example of this phenomenon is the CYP2C19 polymorphism. In this table the most frequent alleles are ...
PharmiWeb

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic ...

SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpointsThe overall safety results in this study were consistent with the established safety profile ...
Seeking Alpha

U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindications Updated U.S. label ...
Medscape

Update on the Pharmacogenomics of Proton Pump Inhibitors

Omeprazole, the prototype drug of PPIs, is metabolized primarily by CYP2C19 to 5-hydroxyomeprazole. 5-hydroxyomeprazole is then transformed into 5-hydroxyomeprazole sulfone by CYP3A4. Omeprazole is ...